Bioventus Inc. Class A Common Stock
Veridion Score
Composite trend over time
Why is BVS moving today?
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BVS.
BVS insider activity
Bioventus Inc. Class A Common Stock
No multi-insider buying cluster in the last 90 days
Net selling: -$1.2M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-14 | 2026-04-10 | Singleton Mark Leonard | Insider | sell | $9.06 | 5,648 | 177,333 | $51K | SEC Form 4 |
| 2026-04-14 | 2026-04-10 | D'Adamio Anthony | Insider | sell | $9.06 | 4,312 | 153,655 | $39K | SEC Form 4 |
| 2026-04-14 | 2026-04-10 | CHURCH KATRINA J | Insider | sell | $9.06 | 1,868 | 64,164 | $17K | SEC Form 4 |
| 2026-03-24 | 2026-03-20 | Singleton Mark Leonard | Insider | sell | $8.64 | 8,091 | 169,981 | $70K | SEC Form 4 |
| 2026-03-17 | 2026-03-13 | Claypoole Robert E | Insider | sell | $8.62 | 14,553 | 135,944 | $125K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 12 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moBVS contract awards, year to date.
Public federal awards linked to this ticker.
BVS lobbying filings, year to date.
Registered lobbying filings matched to Bioventus Inc. Class A Common Stock.